Thursday, June 29, 2017
News

Apollo Hospitals ties up with RMS Regrow for cell-based therapy

   SocialTwist Tell-a-Friend    Print this Page   COMMENT

New Delhi | Monday, 2017 5:45:06 PM IST
 
Apollo Hospitals has partnered with Mumbai-based Regenerative Medical Services (RMS) Regrow to offer a safe and cost-effective cell therapy for cartilage and bone problems for the first time in India.

The partnership will make the cell-based treatment available across all 40 centres of Apollo Hospitals, including Apollo Spectra Hospitals and Apollo clinics in India, the hospital chain said at an event here on Monday.

RMS Regrow, the first "Make in India" company in cell therapy technology, has two treatments: Chondron ACI for knees or cartilage problems and Ossron Autologous Osteoblast Implantation (ABI) for hip joints.

"Nearly 65-70 per cent of people above the age of 40 experience joint problems. The cell therapy may help postpone the need for a replacement surgery and with proper rehabilitation it will also enable a patient to resume normal routine in nearly three months," Prathap C Reddy, Founder-Chairman of Apollo Hospitals told the media.

With the cell-therapy technique, damage to the cartilage can be repaired after the new cultured cartilage is put back into one's knees.

However, for individuals at an advanced stage of osteoarthritis, replacement surgeries will be the best mode of treatment as their cartilages may not be able to regrow.

"Both Ossron and Chondron are efficient in treating a young arthritic knee with sports injuries, accidents and can is an alternative treatment to hip replacements or knee replacements," said Satyen Sanghavi, Chief Scientific Officer at RMS Regrow.

"In the future, the cell therapy-based treatment can also be extended to lengthening of limbs or bones or for maxillofacial defects (defects of the head and neck)," he added.

The company also received a market authorisation approval from the Drug Controller General of India (DGCI) in April this year.

Further, the treatment cost "in India, will be Rs 3.5-4 lakh per patient, which is less than 10 per cent of the cost abroad and will be available in all our hospitals in six months," Reddy said.

--IANS rt/ruwa/dg

( 337 Words)

2017-06-19-17:06:38 (IANS)

Watch News Videos

 
  LATEST COMMENTS (0)
POST YOUR COMMENT
Comments Not Available
 
POST YOUR COMMENT
 
TRENDING TOPICS
 
 
 
CITY NEWS
MORE CITIES
 
MORE HEALTH NEWS
WHO vaccinates 30 million Africans again...
Innovations in medicine needed to cure r...
Nothing sweet about it: Chandigarh's poo...
India top health sector provider to UN...
Autistic adults more consistent in decis...
Online dating abuse likely to affect gir...
More...
 
INDIA WORLD ASIA
DU requested to fix glitches in universi...
President summons Rajya Sabha for monsoo...
HC Chief Justice administers oath to two...
Kochi Rubber Market...
Cabinet gives in-principle approval for ...
Cabinet gives 'in principle' approval fo...
More...    
 
 Top Stories
Two soldiers injured in Pakistan fi... 
Blake Lively, Ryan Reynolds urge pa... 
Trump to attend French Bastille Day... 
Attack confirms need for efforts ag... 
Tommy Hilfiger's daughter Ally is m... 
Hamas begins creating buffer zone a... 
Macron to address joint Parliament ... 
My voice suited Akshay Kumar the mo...